Bexotegrast development in IPF discontinued Clinical oncology program and early-stage programs continue Recent workforce and operational changes align with next steps SOUTH SAN FRANCISCO, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following the review of data from the recently terminated BEACON-IPF Phase 2b/3 clinical trial, the Company has discontinued development of bexotegrast in idiopathic pulmonary fibrosis (IPF). BEACON-IPF Trial Update BEA ...

SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company led oral and poster presentations of clinical and preclinical data this week as part of the American Thoracic Society (ATS) 2025 International Conference, held from May 16-21, 2025. Characterizing the Antifibrotic Activity of Bexotegrast on Distinct Fibroblast Populations in PCLS from Multiple ILD SubtypesIn a featured oral presentation, Johanna Schaub, Ph.D., Director of T ...

Activities supporting the close out of BEACON-IPF continue; topline data expected in the second quarter of 2025 Recently announced strategic realignment of workforce and operations will extend cash runway to support execution of late-stage clinical trials SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today p ...

- Implementation of cost reduction initiatives to position Pliant for execution of late-stage clinical trials - Pliant will reduce its current workforce by approximately 45% - Closing activities for BEACON-IPF trial ongoing; topline data expected in the second quarter of 2025 SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a strategic restructuring of its workforce and other cost saving actions to extend the cash runway to support execut ...

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc (“Pliant” or the “Company”) (NASDAQ: PLRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Pliant and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On Februar ...

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc (“Pliant” or the “Company”) (NASDAQ: PLRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Pliant and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On Februa ...

Core Insights - Pliant Therapeutics, Inc. announced promising interim results from its Phase 1 clinical trial of PLN-101095, showing a 50% objective response rate in patients with advanced or metastatic solid tumors who are refractory to immune checkpoint inhibitors [2][5][6] Group 1: Clinical Trial Details - The trial is evaluating PLN-101095, an integrin αvβ8 and αvβ1 inhibitor, in combination with pembrolizumab in patients with ICI-refractory tumors [2][7] - Three partial responses were observed in cohort three at the highest tested dose of 1000 mg administered orally twice daily [2][5] - The trial has enrolled nine patients across three cohorts, with treatment durations of 14 days followed by combination therapy [3][5] Group 2: Efficacy Observations - Among the six patients treated at the 1000 mg BID dose, three confirmed partial responses were noted, with significant reductions in tumor sizes: 74% for NSCLC, 48% for cholangiocarcinoma, and 42% for melanoma [5][6] - Initial partial responses were observed at Week 10 for NSCLC, Week 34 for cholangiocarcinoma, and Week 18 for melanoma [5] Group 3: Safety and Tolerability - PLN-101095 was generally well tolerated across all doses tested, indicating a favorable safety profile [2][5][6] - The ongoing trial is currently enrolling the fourth cohort, which will evaluate PLN-101095 at a different dosing schedule of 1000 mg three times daily [6] Group 4: Company Background - Pliant Therapeutics is focused on developing novel therapeutics for fibrotic diseases, with PLN-101095 being a key candidate for treating solid tumors [8] - The company has received regulatory designations for its lead product candidate, bexotegrast, indicating its commitment to advancing innovative treatments [8]

SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced that its Board of Directors has unanimously adopted a limited duration stockholder rights agreement (the "Rights Agreement") to protect stockholder interests. The Board resolved to adopt the Rights Agreement in response to recent accumulations of the Company's common stock. The Rights Agreement is intended to reduce the likelihood that any entity, person or group is able to gain control of ...

Core Viewpoint - Pliant Therapeutics is under investigation for potential securities fraud following significant stock price declines related to the discontinuation of its BEACON-IPF Phase 2b trial for bexotegrast, raising concerns about the company's future prospects [1][2][4]. Group 1: Company Actions and Responses - On February 7, 2025, Pliant announced a voluntary pause in enrollment and dosing for the BEACON-IPF Phase 2b trial based on recommendations from the independent Data Safety Monitoring Board (DSMB) [2]. - Following the announcement on February 7, Pliant's stock price dropped by $4.72, or 60.59%, closing at $3.07 per share on February 10, 2025 [3]. - On March 3, 2025, Pliant disclosed the discontinuation of the BEACON-IPF trial due to an imbalance in unadjudicated IPF-related adverse events between treatment and placebo groups, as recommended by both the DSMB and an outside expert panel [4]. - After the March 3 announcement, Pliant's stock price fell by $2.06, or 59.88%, closing at $1.38 per share [5]. Group 2: Market Reactions - Analysts from Wells Fargo and Citi downgraded Pliant's stock following the February 7 announcement, citing uncertainty regarding the future of bexotegrast [2].